Please login to the form below

Not currently logged in
Email:
Password:

Vemlidy

This page shows the latest Vemlidy news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Current HBV therapies, including Gilead’s own Hepsera, Viread and Vemlidy, focuses on inhibiting viral DNA replication but don't completely clear the virus.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... Confirming the CHMP's November approval recommendation, the EC

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of adults and adolescents ... The CHMP's recommendation follows the

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics